NuCana plc announced that the China National Intellectual Property Administration granted a composition‑of‑matter patent (ZL 202010794701.2) for its lead cancer candidate NUC‑7738 on November 5, 2025. The patent protects the chemical structure of the drug and extends the company’s intellectual‑property shield in the world’s largest pharmaceutical market.
The grant adds a critical layer to NuCana’s global IP strategy, which already includes more than 85 issued patents worldwide. By securing protection in China, the company reduces the risk of generic competition in a market that accounts for a significant share of future oncology sales and strengthens its negotiating position with potential partners and payers.
NUC‑7738 is currently being evaluated in a Phase 1/2 study (NuTide:701) in combination with pembrolizumab for patients with PD‑1 inhibitor‑refractory melanoma. The company presented encouraging clinical and translational data at ESMO 2025, showing early signals of efficacy and a favorable safety profile. The new patent therefore supports the commercial potential of the drug as the study progresses and data mature.
CEO Hugh S. Griffith said the CNIPA decision “further strengthens the intellectual‑property protection of NUC‑7738” and highlighted the confidence built by the positive clinical data. He added that the patent “enhances the potential commercial value of the candidate” and underscores NuCana’s commitment to delivering innovative cancer therapies.
Following the announcement, NuCana’s stock rose 8.9% in pre‑market trading on November 5, 2025, reflecting investor confidence in the company’s IP strategy and the promising clinical trajectory of NUC‑7738. The market reaction was driven by the strategic importance of the Chinese patent and the supportive data presented at ESMO, which together signal a stronger commercial outlook for the candidate.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.